 |
 |
GEO help: Mouse over screen elements for information. |
|
| Status |
Public on Jun 18, 2012 |
| Title |
Expression profiling of lung cancer cell lines |
| Organism |
Homo sapiens |
| Experiment type |
Expression profiling by array
|
| Summary |
Purpose: To determine the 8-week disease control rate (DCR) of sorafenib monotherapy in patients with advanced non-small-cell lung cancer (NSCLC) in the BATTLE trial.
Methods: Patients with pre-treated NSCLC, ECOG performance status (PS) 0-2, consented to biopsies to test for biomarker assessment. Sorafenib was given at 400 mg orally twice daily until tumor progression or an unacceptable toxicity. Tumor evaluations were performed at baseline and every 8 weeks. Correlations of outcomes by biomarker groups were analyzed.
Results: 105 patients were eligible and 98 patients were evaluable. Median age was 62 (range 34-81) years, 51% of patients were male, 75% were former/current smokers, and 89% had an ECOG PS of 0-1. Median prior chemotherapies for stage IV NSCLC were two. Median follow-up was 9.4 (range: 1.3-32.2) months. Eight-week DCRs by histology were 59.1%, 57.1%, and 55.6% for adenocarcinomas, squamous cell carcinomas and other histologies respectively. Patients with tumors harboring EGFR mutations had significantly lower 8-week DCR compared to patients with wild-type tumors (23.1% vs. 64.2%, P=0.0119), and patients with tumors harboring K-RAS mutations had the highest 8-week DCR (67%). Most commonly reported treatment-related adverse events include hand-foot syndrome (59.6%), fatigue (42.3%), rash (40.4%), diarrhea (38.5%), and weight loss (38.5%).
Conclusion: 8-week DCR was better in patients treated with sorafenib who had EGFR wild-type tumors (including those with K-RAS mutations) when compared to those who had EGFR mutations. Additional analyses are warranted to further explore the biology of these tumors and related patient outcomes with sorafenib treatment. ClinicalTrials.gov number, NCT00411671.
|
| |
|
| Overall design |
To develop gene expression signatures for in vitro drug response and other phenotypes. To characterize human bronchial epithelial cells (HBECs) and human small airway epithelial cells (HSAECs), which are normal lung cells derived from the bronchus and peripheral areas resp. and were immortalized with CDK4 and hTERT.
Expression profiling was done on 124 NSCLC and 39 SCLC cell lines, using either Illumina HumanWG-6 V3 or HumanHT-12 V4. In addition, 30 HBEC-KTs, 15 HSAEC-KTs and 14 HSAEC-UIs were profiled with Illumina HumanWG-6 V3. (KT: immortalized with CDK4 and hTERT, UI: unimmortalized)
|
| |
|
| Contributor(s) |
Girard L, Minna JD, Gao B |
| Citation(s) |
23091115, 24618618, 32512502 |
| Submission date |
Sep 09, 2011 |
| Last update date |
Jun 22, 2020 |
| Contact name |
Luc Girard |
| E-mail(s) |
Luc.Girard@UTSouthwestern.edu
|
| Organization name |
UT Southwestern Medical Center
|
| Department |
Hamon Center for Therapeutic Oncology Research
|
| Lab |
NB8.114A
|
| Street address |
5323 Harry Hines Blvd
|
| City |
Dallas |
| State/province |
TX |
| ZIP/Postal code |
75390-8593 |
| Country |
USA |
| |
|
| Platforms (2) |
| GPL6884 |
Illumina HumanWG-6 v3.0 expression beadchip |
| GPL10558 |
Illumina HumanHT-12 V4.0 expression beadchip |
|
| Samples (222)
|
|
| Relations |
| BioProject |
PRJNA147685 |
| Supplementary file |
Size |
Download |
File type/resource |
| GSE32036_GSM1682797-GSM1682812_non-normalized.txt.gz |
2.3 Mb |
(ftp)(http) |
TXT |
| GSE32036_RAW.tar |
32.4 Mb |
(http)(custom) |
TAR |
| GSE32036_non-normalized.txt.gz |
35.1 Mb |
(ftp)(http) |
TXT |
| Processed data included within Sample table |
|
|
|
|
 |
Less...
More...